Table 1.
Baseline characteristics of patients (N=614) in the Devenir des Spondyloarthropathies Indifférenciées Récentes cohort with baseline MRI reading split according to the availability of 5-year MRI imaging of the SIJ and/or spine
| Patients with follow-up MRI* (n=155) |
Patients without follow-up MRI (n=459) |
|
| Age at baseline (years) | 33.5 (8.9) | 33.9 (8.7) |
| Female gender, n (%) | 81/155 (52) | 248/459 (54) |
| Symptom duration (years) | 1.4 (0.8) | 1.6 (0.9)† |
| Peripheral arthritis, n (%) | 36/153 (24) | 103/459 (22) |
| Uveitis, n (%) | 12/155 (7.7) | 45/459 (10) |
| Enthesitis, n (%) | 91/155 (59) | 258/459 (56) |
| Dactylitis, n (%) | 22/155 (14) | 64/458 (14) |
| IBD, n (%) | 8/155 (5.2) | 25/459 (6) |
| Psoriasis, n (%) | 30/155 (19) | 77/459 (17) |
| Good response to NSAIDs, n (%) | 136/155 (88) | 397/455 (87) |
| Positive family history, n (%) | 64/145 (44) | 191/435 (44) |
| HLA-B27 positive, n (%) | 98/155 (63) | 269/458 (59) |
| Elevated CRP (≥6 mg/L), n (%) | 41/148 (28) | 133/445 (30) |
| Radiographical sacroiliitis baseline (mNY), n (%) | 21/150 (14) | 65/446 (15) |
| Meeting the ASAS axSpA criteria | 102/154 (66%) | 276/448 (62%) |
| ASDAS-CRP† | 2.7 (0.9) | 2.6 (1.0) |
| BASFI† (0–10) | 3.1 (2.4) | 3.0 (2.2) |
| Use of NSAIDs, n (%) | 147/155 (95) | 424/459 (92) |
| Use of bDMARDs at baseline, n (%) | 0/155 (0) | 0/459 (0) |
All numbers in the table are mean (SD) unless indicated otherwise.
*Patients with both baseline and 5-year MRI available of either the SIJ, spine or both.
†<5% missing data.
ASAS, Assessment of Spondyloarthritis International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARD, biological disease-modifying antirheumatic drug; CRP, C reactive protein; HLA-B27, human leucocyte antigen; IBD, inflammatory bowel disease; mNY, modified New York; NSAID, non-steroidal anti-inflammatory drug; SIJ, sacroiliac joint.